-
Innovative medicine industry is entering a new era, and it is a trend for pharmaceutical companies to walk on multiple legs
Time of Update: 2021-12-27
On the whole, the innovative drug industry has ushered in rapid development, with the number of new drugs approved and the proportion of clinical trial applications reaching new highs year by year .
-
$11.7 billion!
Time of Update: 2021-12-27
For example, as early as September 2014, German industry giant Merck announced that it would acquire Aldrich Pharmaceuticals for US$17 billion in order to expand Merck’s life sciences business .
-
These four clinically urgently needed imported drugs have been approved for use in batches!
Time of Update: 2021-12-27
It is understood that since the Hainan Provincial Food and Drug Administration approved five licensed drugs at the same time on November 26, the approval efficiency of clinically urgently needed imported drugs in the Boao Lecheng International Medical Tourism Pioneer Zone has been greatly improved .
-
The development momentum of domestic medical equipment is fierce
Time of Update: 2021-12-27
It is reported that Yuyue Medical has long focused on independent research and development, and has mastered the core technology of high-end medical devices through technological innovation, broke the foreign technology monopoly, and brought professional health management concepts and advanced product solutions to thousands of hospitals and families.
-
A new change is taking place in the pharmaceutical equipment industry!
Time of Update: 2021-12-27
For example, in the case of a delay in the delivery date of imported equipment, a pharmaceutical machine company in Ningbo has seized the opportunities in the domestic market and continued to invest in new product research and development.
-
Under centralized procurement, the price reduction of unselected original research drugs has also become a trend
Time of Update: 2021-12-27
According to data from Meinenet, in 2020, the total sales of valsartan in Chinese public medical institutions and physical pharmacies in cities in China will exceed 5 billion yuan .
-
Pharmaceutical Affairs has long known that WuXi Biologics intends to repurchase shares not exceeding US$500 million
Time of Update: 2021-12-27
|A quick overview of the content of this issue| ●Hansen Pharma’s clinical trial of antifungal drugs approved ●Shenzhou Cell: Adalimumab injection drug registration application accepted ●Shanghai Pharmaceuticals: The company does not implement consolidated control over Shanghai Pharmaceutical Kangsino ● Deck Pharma-B: Repurchase of 200,000 shares involving 2.
-
With the explosion of the local innovative drug industry, pharmaceutical companies have continuously enhanced their ability to "absorb money"
Time of Update: 2021-12-27
In addition to BeiGene and Dizhe Pharmaceuticals, a number of innovative drug companies such as Rongchang Biologics and Maiwei Biologics, China's new antibody drug giants, have recently been approved for listing on the Science and Technology Innovation Board .
-
The label restrictions are settled!
Time of Update: 2021-12-27
Just a few days ago, the FDA updated the labels of these drugs, requiring patients to use TNF inhibitors before using newer JAK inhibitors for approved indications, such as rheumatoid arthritis .
-
At the end of the year, the wave of mergers and acquisitions of pharmaceutical companies continued!
Time of Update: 2021-12-26
In recent years, due to the difficulty, time-consuming, labor-intensive, and costly research and development of new drugs, many pharmaceutical companies have vigorously made some new investment arrangements in order to increase corporate operating profits, enrich drug pipelines, and reduce R&D expenditures .
-
Over 200 listed companies have been investigated by fund companies!
Time of Update: 2021-12-26
In addition, the companies that Harvest Fund has investigated since December are also mainly in the pharmaceutical and biological, mechanical equipment, and electronics industries .
According to the main content of investor relations activities, the institutions mainly focus on the company’s three major medical hospitals.
-
The production and sales of drugs have become normal, and it is urgent for pharmaceutical companies to accelerate their transformation
Time of Update: 2021-12-26
Recently, the Liaoyang Municipal Market Supervision and Administration Bureau of Liaoning Province issued an announcement on the cancellation of the "Drug Business License" of Liaoning Taixing Pharmaceutical Chain Co.
-
Post more!
Time of Update: 2021-12-26
Judging from the plans of the above-mentioned provinces and cities, it mainly focuses on encouraging the development of market-competitive Chinese medicine equipment, building research and development platforms, gathering and cultivating talents, and transforming innovative achievements to promote the development of the Chinese medicine equipment industry .
-
Innovative Chinese medicines have entered the harvest period, and 2 new drugs have been approved for marketing
Time of Update: 2021-12-26
Jieyu Chufan Capsule is also an innovative traditional Chinese medicine developed on the basis of clinical experience.
-
Within one day, a number of pharmaceutical companies announced that a new class of drug was approved for listing
Time of Update: 2021-12-26
received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, approving the company's independent research and development of Class 1 chemical innovative drugs "BT-101094 Capsule" carries out clinical trials of advanced malignant solid tumors .
-
In order to accelerate the improvement of innovation strength, it has become a trend for pharmaceutical companies to introduce new therapies
Time of Update: 2021-12-26
According to the agreement, Wei Li Zhibo will receive an advance payment of 30 million US dollars, and after reaching clinical development, drug regulatory approval and sales milestones, it will be eligible to receive a total transaction amount of up to 742 million US dollars, and double digits in authorized regions Graded sales royalties .
-
Shandong pharmaceutical companies will win over 4 billion large varieties
Time of Update: 2021-12-26
According to data from Meinenet, the total sales of this product in China's public medical institutions and physical pharmacies in cities in China will exceed 4 billion yuan in 2020 .
-
With four heavy blows in one month, where should the API industry go?
Time of Update: 2021-12-26
In the context of the promising prospects of the API industry, domestic pharmaceutical companies have continued to move, a series of new or expanded large-scale API projects have started one after another, and under the normalization of centralized procurement, many drugs have won the bid through price-for-volume, and pharmaceutical preparations have been brought The expansion of usage also directly drives the increase in the amount of APIs.
-
The mismanagement of private hospitals was cancelled and became a new district of public hospitals!
Time of Update: 2021-12-26
According to the Judgment Document Network, in May 2015, the dean of the hospital contracted the main body of the outpatient building and inpatient ward building of Dancheng County Friendship Hospital and the corresponding ancillary projects to a construction company, and the two parties signed a supplementary agreement.
-
Deck Pharma's first new drug approved in China
Time of Update: 2021-12-26
According to an earlier press release from Deqi Pharmaceuticals, Celiniso is currently the first and only oral XPO1 inhibitor approved by the US FDA and the first to be used for the treatment of multiple myeloma and diffuse large B-cell lymphoma Drugs .
